Mainstay Medical Limited Sustainability Profile
Mainstay Medical Limited, headquartered in Ireland (IE), is a pioneering company in the medical device industry, specialising in innovative solutions for chronic pain management. Founded in 2008, Mainstay has made significant strides with its flagship product, the ReActiv8 system, designed to treat patients suffering from chronic low back pain through neuromodulation. With a focus on enhancing patient quality of life, Mainstay Medical operates primarily in Europe and North America, positioning itself as a leader in the field of neuromodulation therapies. The company’s commitment to research and development has led to notable achievements, including successful clinical trials that underscore the efficacy of its products. Mainstay Medical continues to redefine pain management, offering unique solutions that stand out in a competitive market.
DitchCarbon Score
How does Mainstay Medical Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mainstay Medical Limited's score of 3 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mainstay Medical Limited's reported carbon emissions
Mainstay Medical Limited, headquartered in Ireland (IE), currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing carbon emissions at this time. It is important to note that Mainstay Medical Limited is a current subsidiary and may inherit emissions data from its parent organization. However, no specific emissions data or climate initiatives have been provided from the parent company or any other sources. As the company continues to develop its sustainability strategy, it may consider adopting industry-standard climate commitments and reduction targets in the future to align with global efforts to mitigate climate change.
How Carbon Intensive is Mainstay Medical Limited's Industry?
How Carbon Intensive is Mainstay Medical Limited's Location?
Mainstay Medical Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mainstay Medical Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
